Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Date:2/24/2009

(18,855) (32,796) Maturities of investments 587,832 591,202 Sales of investments 70,396 2,057 Purchases of investments (475,316) (593,118) Net cash provided by (used in) investing activities 274,652 (32,655) Cash flows from financing activities: Issuance of common stock, net of issuance costs 384 3,780 Payments of loan and capital lease obligations (2,368) (2,895) Repayments of convertible subordinated notes (47,757) (102,653) Net cash used in financing activities (49,741) (101,768) Effect of exchange rates on cash and cash equivalents 162 654 Net increase in cash and cash equivalents $79,291 $12,533 Cash and cash equivalents at beginning of year 76,293 63,760 Cash and cash equivalents at end of year $155,584 $76,293
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
2. Nektar Announces Retirement of Irwin Lerner from Board of Directors
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
10. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
11. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... 9 The results of a new study on immune-based ... sites around the country, will be published in the December ... MD, MS, director of the Butler Hospital Memory and Aging ... Warren Alpert Medical School of Brown University, says that this ...
... , , QUEBEC CITY, Dec. 9 /PRNewswire-FirstCall/ ... AEZ) (the "Company"), a global biopharmaceutical company focused on ... appointment of Pierre Lapalme to its Board of Directors. ... has over the course of his career held numerous ...
... , OXFORD, England, December ... Recent Recruitment of Senior Antibody Industry,Leaders and Highlights OBT,s Growth ... Oxford BioTherapeutics (OBT) has today announced the appointment of ... experience to OBT at an exciting phase in the Company,s,development, ...
Cached Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2AEterna Zentaris Announces Appointment of New Board Member 2Oxford BioTherapeutics Appoints Michael Moore as Chairman 2Oxford BioTherapeutics Appoints Michael Moore as Chairman 3Oxford BioTherapeutics Appoints Michael Moore as Chairman 4
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... function and increase the survival rate of naturally ... School of Pharmaceutical Sciences, Southwest University, China performed ... administered with low dose of levothyroxine for 3 ... exhibited an obvious improvement in cognitive and an ... The underlying mechanism was demonstrated that levothyroxine treatment ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... is helping to reduce the drug cravings of addicted rats. ... some parts of the brain lose glutamate receptors from the ... neurons. The researchers have sidestepped this problem by crafting a ... glutamate receptor and, once inside a neuron, serves as a ...
... discovered in tiny snow fleas by Queen's University researchers ... transplantation. , Drs. Laurie Graham and Peter Davies, from ... produced by the fleas to protect themselves against freezing ... Celsius degrees. This would allow organs to be stored ...
... zebrafish may be able to play a critical role in ... that can lead to it - and identified one gene ... , The findings were published in a professional journal, Proceedings ... State University and two Boston hospitals, the Brigham and Women's ...
Cached Biology News:Grabbing addiction by the tail 2Grabbing addiction by the tail 3New antifreeze protein found in fleas may allow longer storage of transplant organs 2Zebrafish may hold key to improved cancer research 2Zebrafish may hold key to improved cancer research 3
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Recombinant Rat Fas Ligand/TNFSF6...
Request Info...
FGF Receptor 1 Antibody...
Biology Products: